CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective vigilantly but unsuccessfully to develop an one-time therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be being used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination therapy in the healing of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my past several shares. My first CytoDyn post, “CytoDyn: What In order to Do When It’s Too Good To Be True?”, set away all of the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such an extremely promotional picture in the Uptick Newswire job interview that I came away with a bad opinion of the company.

Irony of irony, my bad impression of the business has grown steadily, though the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the therapy and prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s payment of $3.5 million transfers ownership of this know-how as well as linked intellectual property from Progenics to CytoDyn, and approximately twenty five million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 huge number of) plus the first new drug program endorsement ($five million), and also royalty payments of five % of net sales upon commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to acquire a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and many therapies, it has this single remedy and a “broad pipeline of indications” as it puts it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially beneficial therapy in dozens of indications.

The opening banner of its on its site (below) shows an energetic company with diverse interests albeit focused on leronlimab, several disease sorts, multiple delivering presentations in addition to multiple publications.

Might all of it be smoke and mirrors? That’s a question I have been asking myself with the really start of my interest in this organization. Judging by the multiples of thousands of various comments on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this particular question.

CytoDyn is a classic battleground, or even some might say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News